IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11071780 B1

PDFFull Text
Date of Patent:
Jul. 27, 2021

Filed:

Dec. 28, 2018

Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab

Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventors:

Robert L. Vitti, Old Tappan, NJ (US);

Kristine A. Erickson, Roxbury, CT (US);

Karen W. Chu, White Plains, NY (US);

Stanley J. Wiegand, Hopewell Junction, NY (US);

Jingtai Cao, White Plains, NY (US);

Ivan B. Lobov, New York, NY (US);

Saurabh Wadhwa, Nanuet, NY (US);

Kenneth S. Graham, Pleasant Valley, NY (US);

Daniel Dix, LaGrangeville, NY (US);

Assignee:

REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US);

Attorneys:

Karl Bozicevic

Bozicevic Field & Francis LLP

Primary Examiner:

Claire Kaufman

Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 38/18 (2006.01); A61K 38/17 (2006.01); C07K 16/22 (2006.01); A61K 9/00 (2006.01); A61K 47/02 (2006.01); A61K 47/26 (2006.01); C07K 14/71 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 9/0048 (2013.01); A61K 38/179 (2013.01); A61K 39/39591 (2013.01); A61K 47/02 (2013.01); A61K 47/26 (2013.01); C07K 14/71 (2013.01); C07K 16/22 (2013.01); C07K 16/46 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2317/21 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01);
Abstract

The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).

Find Patent Forward Citations

Loading…